Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 65
Journal of gynecologic oncology · Nov 2025
uterine carcinosarcoma
This observational study analyzed 65 uterine carcinosarcoma cases, assigning molecular subtypes by POLE sequencing and IHC for MMR and p53, and quantified PD-L1 and tumor-associated immune cells using QuPath. PD-L1 tumor density and stromal CD8 and CD163 densities were significantly associated with molecular subtype. Patients with POLEmut or dMMR subtypes showed a trend toward better prognosis; high tumor PD-L1 density was associated with better survival while high stromal CD163 density was associated with worse survival.
Reported effects: POLEmut cases (%) 1.5%, n=65 · dMMR cases (%) 16.9%, n=65 · +5 more
Key findings
- Among 65 UCS cases, 1 case (1.5%) was POLEmut, 11 cases (16.9%) were dMMR, 32 cases (49.3%) were p53mut, and 21 cases (32.3%) were NSMP.
- The positive density of PD-L1 in tumor was significantly associated with molecular subtypes (p=0.022).
- The positive density of CD8 in stroma was significantly associated with molecular subtypes (p=0.036).
- The positive density of CD163 in stroma was significantly associated with molecular subtypes (p=0.025).
- Patients with POLEmut and dMMR subtypes had a relatively better prognosis trend than patients with NSMP and p53mut subtypes.
- High positive density of PD-L1 in tumor was associated with significantly better prognosis.
- High positive density of CD163 in stroma was associated with significantly worse prognosis.
Limitations: Observational study design—associations cannot establish causality.; Relatively small sample size (n=65), limiting statistical power and generalizability.; Extremely small number of POLEmut cases (only 1 case), preventing meaningful conclusions for that subtype.; Prognostic associations reported without external validation or reported multivariable adjustment details in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 9
Translational oncology · Nov 2025
uterine carcinosarcoma
The authors performed multi-omic profiling (whole-genome sequencing, RNA-seq, and enzymatic methylation sequencing) on microdissected epithelial and mesenchymal components from uterine carcinosarcoma samples, and assessed the tumour microenvironment with multiplex immunohistochemistry and computational pathology. They found low median tumor mutation burden, frequent TP53 mutations and recurrent copy-number amplifications, broadly similar genomic and epigenomic profiles between epithelial and mesenchymal regions, global hypomethylation with different pathway enrichment in each component, and higher tumour-associated macrophage and PD-L1+ cell density in the mesenchymal component. The study is descriptive and based on a small number of cases.
Reported effects: median TMB 0.97, n=18 · TP53 mutation frequency 94%, n=18 · +9 more
Key findings
- WGS and EM-seq of 18 samples from 9 patients revealed a low tumor mutation burden (TMB; median = 0.97 mutations/Mb) and no evidence of microsatellite instability (MSI).
- Driver mutations were identified in TP53 (94 %), PIK3CA (33 %), and PPP2R1A (22 %).
- Copy-number analysis revealed recurrent amplifications of MYC (67 %), PIK3CA (61 %), CCNE1 (56 %), AKT2 (44 %), and SMARCA4 (39 %).
- Comparative analysis of the epithelial (C) and mesenchymal (S) regions revealed no significant differences in mutation frequency, copy-number, transcriptomic and methylomic profiles.
- Both regions exhibited global hypomethylation, with functional enrichment for xenobiotic metabolism pathways in C and epithelial-to-mesenchymal transition pathways in S regions.
- Comparative mIHC performed on 21 cases showed similar T cell and B cell densities, but a higher density of tumour-associated macrophages and PD-L1+ cells in the S component.
- Computational morphologic analysis showed substantial histomorphologic heterogeneity within and across UCS cases.
Limitations: Small sequencing sample size (18 samples from 9 patients) limits generalizability.; Observational, descriptive study without functional validation of genomic/epigenomic findings.; No clinical outcome or treatment-response data reported to link molecular features to prognosis or therapy response.; mIHC analysis was performed on a separate/expanded cohort of 21 cases but remains limited in size.; Heterogeneity within tumors may limit ability to generalize findings from microdissected regions..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 97
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Oct 2025 · multicenter retrospective study
uterine carcinosarcomaendometrial carcinosarcomaendometrial neoplasms
This multicenter retrospective study looked at 97 people with very early uterine carcinosarcoma that had not invaded the muscle layer of the uterus. The researchers compared outcomes by where the tumor was found and by whether patients received chemotherapy. Recurrence was common, mostly at distant sites, and the study did not find statistically significant survival differences with chemotherapy.
Reported effects: 5-year recurrence-free survival 63.5% [53.4–75.4], n=97 · overall survival 72% [62.6–82.9], n=97
Key findings
- 29 of 97 patients (29.9%) had a recurrence, mostly with a distant pattern of relapse.
- The 5-year recurrence-free survival was 63.5% and overall survival was 72.0%.
- No significant differences were observed in recurrence-free survival and overall survival based on tumor status.
- The difference in recurrence-free survival and overall survival was not statistically significant based on receipt of chemotherapy.
Limitations: Retrospective observational design; Rare disease with small sample size; Non-randomized treatment selection; Follow-up for survival analysis was limited to 5 years; Potential confounding by indication; No chemotherapy regimen, dose, or timing details provided in the abstract.
This study evaluates outcomes in a rare endometrial cancer subtype and compares adjuvant chemotherapy versus no chemotherapy after surgery.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
OtherMechanismReported positiveLimited evidenceTier 3 · early humann = 21
NPJ digital medicine · Jul 2025 · Proof-of-concept computational digital-twin development integrating institutional/published cases and literature-derived data
rare gynecological tumorsuterine carcinosarcoma
The authors developed a proof-of-concept large language model (LLM)-enabled digital twin that integrates clinical and biomarker data from 21 cases and 655 publications to generate tailored treatment plans. Applied to metastatic uterine carcinosarcoma, the system identified therapeutic options that might be missed by single-source analyses and efficiently modeled individual patient trajectories. The authors argue that defining tumors by biology rather than organ could enable more personalized care for rare gynecological tumors.
Reported effects: integrated_cases_n 21 · literature_publications_n 655
Key findings
- Developed an LLM-enabled digital twin integrating clinical and biomarker data from institutional and published cases (n = 21) and literature-derived data (n = 655 publications).
- Created tailored treatment plans for metastatic uterine carcinosarcoma using multi-source data integration.
- Identified treatment options potentially missed by traditional, single-source analysis.
- LLM-enabled digital twins can efficiently model individual patient trajectories.
- Shifting to a biology-based rather than organ-based tumor definition could enable more personalized care for rare gynecological tumors.
Limitations: Proof-of-concept computational study without prospective clinical validation.; Small number of integrated cases (n = 21).; No clinical outcomes or patient-level efficacy/safety data reported.; Relies on literature-derived data and published cases which may have heterogeneity and publication bias.; Abstract does not report external validation or comparison to standard-of-care decision processes..
Demonstrates a computational approach for biomarker-driven treatment matching in rare gynecological tumors using LLMs; clinical impact not evaluated in this study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 51
Gynecologic oncology · Jul 2025 · observational genomic profiling of tumor samples
uterine carcinosarcoma
The authors performed next-generation sequencing of tumor DNA from 51 uterine carcinosarcoma patients, analyzing mutations, copy-number changes, microsatellite instability, tumor mutational burden, and homologous recombination deficiency. They found TP53 alterations were most frequent (88%), with PIK3CA (35%) and CCNE1 (33%) also common; most cases had a TP53-mutant profile, 11 were HR-deficient, and 7 samples had high TMB (≥16). Carcinoma and sarcoma components showed concordant gene variants but divergent copy-number changes, supporting a monoclonal origin. No molecular variables were statistically significant in survival analysis, but 45 cases (88%) harbored alterations that the authors considered potentially targetable by existing therapies.
Reported effects: n_included 51, n=51 · TP53_alteration_frequency 88%, n=51 · +9 more
Key findings
- Among 51 included patients, TP53 was most frequently altered (88%), followed by PIK3CA (35%) and CCNE1 (33%).
- Separate analysis of carcinoma and sarcoma components revealed concordant gene variants but divergent copy number variations.
- Based on molecular classification, the majority of the cases 44 (84.6%) had a TP53-mutant profile.
- Eleven cases were homologous recombination (HR) deficient.
- Seven samples (14%) had high tumor mutational burden (TMB ≥16).
- Key altered pathways were TP53, RTK/RAS, PI3K, and cell cycle pathways.
- Alterations that could serve as possible molecular targets for existing therapies were identified in 45 cases (88%).
- No molecular variables were statistically significant in the survival analysis.
Limitations: Observational genomic profiling without an interventional component.; Modest sample size (51 patients), limiting statistical power.; Survival analysis found no statistically significant molecular associations.; Carcinoma and sarcoma components were analyzed separately only "when possible," implying incomplete paired-component data in some cases.; Clinical impact of the identified potentially targetable alterations was not tested in patients (no interventional/therapeutic data)..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Animal studyReported positivePreclinical onlyTier 2 · animaln = 72
Gynecologic oncology · Jun 2025 · archival tissue analysis plus patient-derived organoid and xenograft preclinical study
This study looked at TROP2 levels in uterine carcinosarcoma samples and tested the TROP2-targeting antibody-drug conjugate sacituzumab govitecan in patient-derived organoid and xenograft models. Most tumors had detectable TROP2, and the organoid models responded to the drug in a dose-dependent way. In two xenograft models, tumor volume was lower with sacituzumab govitecan than without it.
Reported effects: TROP2 expression in primary UCSs 90%, n=72 · Higher TROP2 expression by histologic subtype, p p < 0.001 and p = 0.022, n=72 · +2 more
Key findings
- TROP2 protein and mRNA were detected in at least 90% of primary uterine carcinosarcomas.
- Tumors with a predominant carcinomatous component or homologous differentiation had higher TROP2 expression than those with predominant sarcomatous component or heterologous differentiation.
- All 9 uterine carcinosarcoma organoid models responded in a dose-dependent manner to sacituzumab govitecan.
- Both xenograft models showed significant reduction in tumor volume with sacituzumab govitecan.
Limitations: Preclinical study; findings are from archival tissues, organoids, and mouse xenografts, not patients.; Only 2 xenograft models were tested.; No clinical outcomes, safety data, or survival data in humans were reported.; The abstract does not provide dosing details or treatment duration..
Supports preclinical exploration of TROP2-targeted therapy in uterine carcinosarcoma.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text